Durham T M, Hodges E D, Harper J, Green J G, Tennant F
UNMC General Practice Residency Program, Department of Pathology, Diagnosis and Radiology, UNMC College of Dentistry, Omaha, NE.
Pediatr Dent. 1993 Jul-Aug;15(4):282-7.
This report describes identification of Factor VIII inhibitor in a patient who then received immune tolerance therapy. The precipitating event was a traumatic orofacial injury that was nonresponsive to traditional factor-replacement therapies. An inhibitor complicates medical and dental management of the hemophiliac patient because it counteracts usual techniques of hemorrhage control using coagulation agents derived from Factor VIII (Monoclate--Armour, Blue Bell, PA). Successful identification and management of the inhibitor patient require communication and consultation between the physician and dentist, up-to-date knowledge regarding the hemophiliac patient's bleeding and infusion history and aggressive application of local adjunctive hemostatic therapies.
本报告描述了一名接受免疫耐受治疗的患者体内VIII因子抑制剂的鉴定情况。引发事件是一次创伤性口腔面部损伤,该损伤对传统的因子替代疗法无反应。抑制剂使血友病患者的医疗和牙科治疗变得复杂,因为它会抵消使用源自VIII因子的凝血剂(Monoclate - 阿摩尔公司,宾夕法尼亚州蓝铃市)控制出血的常用技术。成功鉴定和管理抑制剂患者需要医生和牙医之间进行沟通与协商,掌握有关血友病患者出血和输注史的最新知识,并积极应用局部辅助止血疗法。